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Abstract
Cancer stem cells (CSCs) are resistant to chemo- and 
radio-therapy,  and  can  survive  to  regenerate  new 
tumors. This is an important reason why various an-
ti-cancer therapies often fail to completely control tu-
mors, although they kill and eliminate the bulk of can-
cer cells. In this study, we determined whether or not 
adenine nucleotide translocator-2 (ANT2) suppression 
could also be effective in inducing cell death of breast 
cancer stem-like cells. A sub-population (SP; CD44
+/ 
CD24
-) of breast cancer cells has been reported to have 
stem/progenitor cell properties. We utilized the ad-
eno-ANT2 shRNA virus to inhibit ANT2 expression and 
then observed the treatment effect in a SP of breast can-
cer cell line. In this study, MCF7, MDA-MB-231 cells, 
and breast epithelial cells (MCF10A) mesenchymally- 
transdifferentiated  through  E-cadherin  knockdown 
were used. ANT2 expression was high in both stem-like 
cells and non-stem-like cells of MCF7 and MDA-MB-231 
cells, and was induced and up-regulated by mesenchymal 
transdifferentiation  in  MCF10A  cells  (MCF10A
EMT). 
Knockdown of ANT2 by adeno-shRNA virus efficiently 
induced apoptotic cell death in the stem-like cells of 
MCF7 and MDA-MB-231 cells, and MCF10A
EMT. Stem- 
like cells of MCF7 and MDA-MB-231, and MCF10A
EMT 
cells exhibited increased drug (doxorubicin) resist-
ance, and expressed a multi-drug resistant related mol-
ecule, ABCG2, at a high level. Adeno-ANT2 shRNA vi-
rus markedly sensitized the stem-like cells of MCF7 and 
MDA-MB-231, and the MCF10A
EMT cells to doxorubicin, 
which  was  accompanied  by  down-regulation  of 
ABCG2. Our results suggest that ANT2 suppression by 
adeno-shRNA virus is an effective strategy to induce 
cell  death  and  increase  the  chemosensitivity  of 
stem-like cells in breast cancer.
Keywords: ABCG2 protein, human; adenine nucleo-
tide translocator 2; drug therapy, combination; gene 
therapy; neoplastic stem cells; RNA, small interfering 
Introduction
Although conventional chemotherapy kills most 
tumor cells, it is believed to leave some cells behind, 
which have proposed to serve as the source of 
recurrence. The cells that tend to remain are thought 
to be cancer stem cells (CSCs) (Dean et al., 2005). 
These CSCs have been found to be resistant to 
many current cancer treatments, including chemo- 
and radio-therapy (Wulf et al., 2001; Liu et al., 2006; 
Phillips et al., 2006; Hermann et al., 2007; Todaro et 
al., 2007; Ma et al., 2008). Further, they demonstrate 
a capacity for self-renewal and generation of hetero-
geneous progeny (Al-Hajj and Clarke, 2004; Ponti et 
al., 2005; Vermeulen et al., 2008). These cells can 
be distinguished from their non-tumorigenic counter-
parts by a specific cell surface marker profile. Breast 
cancer cells with high levels of CD44 (CD44
high) and 
absent or low CD24 (CD24
neg/low) expression have 252    Exp. Mol. Med. Vol. 44(4), 251-259, 2012
Figure 1. ANT2 is highly expressed in both cancer stem-like cells and 
non-cancer stem-like cells of breast cancer. (A) CD44+/CD24- fractions 
were sorted from MDA-MB-231 and MCF7 cells using the MACS. The 
sorting purities were confirmed by FACS analysis. RT-PCR to detect the 
level of ANT2 expression in unsorted and CD44+/CD24- sorted cells. 
Total RNA was extracted from respective cells and subjected to RT-PCR 
using specific primers for human ANT2 or β-actin (internal control). 
These data were confirmed by the qRT-PCR and normalized by β-actin 
mRNA. (B) MCF10A cells were transfected with scramble shRNA or 
E-cadherin shRNA (each 1 μg). EMT-associated morphology was de-
tected by microscope, and the change in ANT2 expression was detected 
by RT-PCR.
functional characteristics of CSCs (Thompson et al., 
1992; Gordon et al., 2003; Charafe-Jauffret et al., 
2006; Elstrodt et al., 2006). Additionally, CD24 is 
expressed in differentiated cells, whereas CD44 is 
expressed in more progenitor-like cells. The CD44 
level has been found to be directly correlated with 
metastasis in breast cancer. Specifically, it has been 
reported that breast cells of the CD44+/CD24- 
phenotype express genes that are involved in cell 
motility and angiogenesis, are more mesenchymal, 
motile, and are predominately estrogen receptor- 
negative (Sheridan et al., 2006; Shipitsin et al., 
2007). Hoechst33342 dye efflux, suspension sphere 
assays, and serial transplantation have also been 
proposed methods for identifying and separating 
CSCs from solid tumors (Pearce and Bonnet, 2007). 
However, the most effective method of identifying 
these cells, which may be morphologically indistinct 
from the bulk of the tumor, has been through 
differential cell surface protein expression.
    CSCs are more resistant to chemo- and radio- 
therapy than non-CSCs (Wulf et al., 2001; Dean et 
al., 2005; Liu et al., 2006; Phillips et al., 2006; 
Hermann et al., 2007; Todaro et al., 2007; Ma et al., 
2008), they exhibit multi-drug resistance (MDR) 
properties, and ABCG2⁄BCRP is particularly 
overexpressed in CSCs (Dean et al., 2005). The 
ATP-binding cassette membrane transporter, 
ABCG2/BCRP, functions as an energy-dependent 
efflux pump, and the expression of ABCG2 has 
been associated with multi-drug resistance. More 
significantly, ABCG2 has been identified as the 
molecular determinant for the sub-population (SP; 
CD44+/CD24-) phenotype and has been postulated 
as a universal stem cell marker (Zhou et al., 2001; 
Schinkel and Jonker, 2003). Moreover, the induction 
of an epithelial-mesenchymal transition (EMT) in 
normal or neoplastic mammary epithelial cell 
populations has been shown to result in the 
enrichment of cells with stem-like properties (Morel 
et al., 2008). We demonstrated herein that 
immortalized breast epithelial cells experimentally- 
induced into an EMT also exhibited an increased 
ANT2 expression.
    ANT2 is specifically expressed in undifferentiated 
cells or tissues that are able to proliferate and 
regenerate (e.g., lymphocytes, kidney, and liver; 
Gross et al., 1999; Suliman et al., 2001; Jang et al., 
2008). The expression of ANT2 was recently shown 
to be up-regulated in several hormone-dependent 
cancers (Doerner et al., 1997), and the induction of 
ANT2 expression in cancer cells has been directly 
associated with glycolytic metabolisms, raising a 
question regarding the role of ANT2 during 
carcinogenesis (Stepien et al., 1992; Faure Vigny et 
al., 1996; Luciakova et al., 2003; Chevrollier et al., 
2005a, 2005b, 2005c; Le Bras et al., 2006). 
Mesenchymal stem cells (MSCs) also require a high 
energy supply, and in particular, glycolytic metabolism 
and oxidative phosphorylation are increased, requiring 
increased expression of related genes such as 
ANT2 (Kong et al., 2011). 
    According to our previous study, ANT2 suppression 
by a DNA vector based RNA interference approach 
expressing short hairpin RNA (shRNA) resulted in 
ATP depletion from breast cancer cells and induced 
cell death (Jang et al., 2008). Based on this 
background, we hypothesized that the knockdown 
of ANT2 using ANT2 shRNA systems might be able 
to induce apoptotic cell death and increase 
chemosensitivity in breast cancer stem-like cells. 
Herein, we show that adno-ANT2 shRNA virus is 
also cytotoxic to breast cancer stem-like cells, and 
that sensitizing the breast cancer stem-like cells to 
chemotherapeutic agents would be effective in the 
control of breast cancer.Therapy of breast cancer stem-like cells    253
Figure 2. Adeno-ANT2 shRNA virus 
effectively induces apoptosis in can-
cer stem-like cells of a breast can-
cer cell line (stem-like cells). (A) 
CD44+/CD24- fractions were sorted 
from MDA-MB-231 and MCF7 cells 
using the MACS. The sorting purities 
were confirmed by FACS analysis. 
Cells were infected with adeno- 
scramble shRNA virus or adeno- 
ANT2 shRNA virus. After 24 h of 
treatment with adeno-virus, cells 
were stained with AnnexinV and PI 
and analyzed by flow cytometry. (B) 
MCF10A cells were transfected with 
scramble shRNA or E-cadherin 
shRNA (each 1 μg). After 24 h, cells 
were re-infected with adeno-scramble 
shRNA virus or adeno-ANT2 shRNA 
virus. After 24 h of treatment with 
adeno-virus, cells were stained with 
AnnexinV and PI and analyzed by 
flow cytometry. 
Results 
ANT2 expression was high in breast cancer stem-like 
cells and non-stem-like cells of breast cancer cell 
lines, and knockdown of ANT2 by adeno-shRNA virus 
efficiently induced cell death
To determine the levels of expression of ANT2 in 
both cancer stem-like cells and non- stem-like of a 
human breast cancer cell line, we first isolated 
progenitor cells based on the cell surface 
expression of CD44 and CD24 (Thompson et al., 
1992; Gordon et al., 2003; Charafe-Jauffret et al., 
2006; Elstrodt et al., 2006) and examined ANT2 
mRNA levels in unsorted and sorted cell populations. 
The percentage of CD44+/CD24- cells was ＞80% 
in MDA-MB-231 cells and ＜10% in MCF7 cells 
(Supplementary Data 1). Moreover, aldehyde 
dehydrogenase (ALDH) activity was used as a 
functional marker for “stem-likeness” (data not 
shown). RT-PCR showed that ANT2 mRNA was 
highly expressed both in the mixed (unsorted) cell 
and sorted population (CD44+/CD24-), and a similar 
result was obtained by the real-time PCR method 
(Figure 1A). In addition, we sought to obtain a 
population of stem-like cells from a human 
mammary gland epithelial cell line (MCF10A) by 
inducing the population of stem-like cells to pass 
through an epithelial-mesenchymal transition (EMT). 
To this end, we modified MCF10A experimentally by 
shRNA-mediated inhibition of E-cadherin (MCF10A
EMT). 
Confirming previous reports, an E-cad shRNA 
triggered an EMT and resulted in acquisition of the 
mesenchymal phenotype (Figure 1B). Interestingly, 
ANT2 expression was induced and up-regulated in 
MCF10A cells with EMT induction (Figure 1B). 
Taken together, we demonstrated high expression 
of ANT2 in human breast cancer and mesen-
chymally transdifferentiated breast epithelial cells 
(MCF10A
EMT). Knockdown of ANT2 by adeno-shRNA 
virus (Supplementary Data 2) efficiently induced 
apoptotic cell death in CD44+/CD24-sorted stem- 
like cells of MDA-MB-231 and MCF7 (50-60%), and 
MCF10A
EMT (30-40%) cells (Figures 2A and 2B). 
These data indicated that ANT2 suppression by 
shRNA could be utilized for an effective therapy of 
breast cancer stem-like cells. 
Adeno-ANT2 shRNA virus suppressed tumor sphere 
formation of stem-like cells of breast cancer 
Tumor sphere (or mammosphere) formation is 
known as a characteristic feature of breast CSCs, 
and can be used for in vitro measurement of CSC 
activity. Adeno-ANT2 shRNA virus-treated progenitor 
cells had an approximate 10-fold decrease in tumor 
sphere-forming ability relative to adeno-scramble 
shRNA virus-treated stem-like cells (Figure 3). We 
also assayed the tumor sphere-forming ability of 
MCF10A
EMT cells, but we did not obtain similar 
results. In our experiments, a single transfection of 
adeno-shRNAs achieved ＞80% knockdown 
(Supplementary Data 2) that lasted 10-14 days 
post-transfection, then progressively diminished. 254    Exp. Mol. Med. Vol. 44(4), 251-259, 2012
Figure 3. Adeno-ANT2 shRNA virus suppresses sphere formation of 
cancer stem-like cells of a breast cancer cell line. (A) CD44+/CD24- frac-
tions were sorted from MDA-MB-231 and MCF7 cells using the MACS. 
The sorting purities were confirmed by FACS analysis. Cells were in-
fected with adeno-scramble shRNA virus or adeno-ANT2 shRNA virus. 
After 24 h, single-cell suspensions were plated (30,000 cells/well) in 
6-well ultra-low attachment plates in F12 + 5% FBS, insulin, and 
hydrocortisone. Mammospheres were cultured for 8 days, and those col-
lected from non-adherent cultures were counted.
Figure 4. Adeno-ANT2 shRNA virus enhances chemosensitivity of pro-
genitor cells of a breast cancer cell line. (A) CD44+/CD24- fractions were 
sorted from MDA-MB-231 using the MACS. The sorting purities were 
confirmed by FACS analysis. Unsorted or CD44+/CD24- sorted cells 
were infected with adeno-scramble shRNA virus or adeno-ANT2 shRNA 
virus. After 24 h of treatment with adeno-virus, cells were treated with 
doxorubicin, and 12 h later, a cytotoxicity assay of cells was performed 
using CCK8 assay kits. (B) CD44+/CD24- fractions were sorted from 
MCF7 using the MACS. The sorting purities were confirmed by FACS 
analysis. Unsorted or CD44+/CD24- sorted cells were infected with ad-
eno-scramble shRNA virus or adeno-ANT2 shRNA virus. After 24 h of 
treatment with adeno-virus, cells were treated with doxorubicin, and 12 h 
later, a cytotoxicity assay of cells was performed using CCK8 assay kits. 
(C) MCF10A cells were transfected with scramble shRNA or E-cadherin 
shRNA (each 1 μg). After 24 h, cells were re-infected with ad-
eno-scramble shRNA virus or adeno-ANT2 shRNA virus. After 24 h of 
treatment with adeno-virus, cells were treated with doxorubicin, and 12 h 
later, a cytotoxicity assay of cells was performed using CCK8 assay kits.
Taken together, these results implied that adeno- 
ANT2 shRNA virus suppressed the tumor sphere- 
forming CSC activity of stem-like cells of breast 
cancer. 
Stem-like cells of breast cancer cell lines exhibited 
drug resistance, and adeno-ANT2 shRNA 
virus-enhanced chemosensitivity 
Treatment of cancer with chemotherapeutic agents 
has often led to an enrichment of the CSC 
population which has frequently shown drug 
resistance (Dean et al., 2005). We isolated stem-like 
cells, and examined their sensitivity to doxorubicin 
in unsorted and sorted cell populations. The 
percentage of CD44+/CD24- cells was higher in 
MDA-MB-231 (80%) than MCF7 cells (10%), and 
unsorted MDA-MB-231 cells were resistant to 
doxorubicin compared with MCF7 cells, which are 
doxorubicin-sensitive. However, in both cell lines, the 
stem-like cell population showed strong resistance 
to doxorubicin (Figures 4A and 4B). Accordingly, we 
assessed the chemosensitizing effects of adeno- 
ANT2 shRNA virus on unsorted and sorted (stem-like) 
cells, and showed that adeno- ANT2 shRNA virus 
markedly sensitized unsorted cells and sorted 
(stem-like cell) MDA-MB-231 and MCF7 cells to 
doxorubicin (Figures 4A and 4B). We also showed 
that MCF10A
E-cad shRNA cells were more resistant to 
doxorubicin than MCF10A
control shRNA cells and that 
adeno-ANT2 shRNA virus sensitized not only 
MCF10A
control shRNA, but also MCF10A
E-cad shRNA to 
doxorubicin (Figure 4C). Therapy of breast cancer stem-like cells    255
Figure 5. ABCG2 is highly expressed in cancer stem-like cells of a 
breast cancer cell line and down-regulated by ANT2 shRNA. (A) 
CD44+/CD24- fractions were sorted from MDA-MB-231 and MCF7 cells 
using the MACS. The sorting purities were confirmed by FACS analysis. 
RT-PCR to detect the levels of ABCG2 expression in unsorted and 
CD44+/CD24- sorted cells. Total RNA was extracted from respective 
cells and subjected to RT-PCR using specific primers for human ABCG2 
or β-actin (internal control). MCF10A cells were transfected with scram-
ble shRNA or E-cadherin shRNA (each 1 μg), and ABCG2 expression 
was detected by RT-PCR. (B) Western blotting for identifying the regu-
lation of ABCG2 protein levels by adeno-ANT2 shRNA virus. Unsorted or 
CD44+/CD24- sorted cells were infected with adeno-scramble shRNA vi-
rus or adeno-ANT2 shRNA virus. After 24 h of treatment with ad-
eno-virus, cell extracts were prepared for performing western blotting 
with anti-ABCG2 and β-actin antibodies. MCF10A cells were transfected 
with scramble shRNA or E-cadherin shRNA (each 1 μg), re-infected with 
adeno-ANT2 shRNA virus, and ABCG2 protein levels were detected by 
western blot.
Figure  6. ANT2 shRNA inhibits ABCG2 activity in cancer stem-like cells of a breast cancer cell line. CD44+/CD24- population from MCF7 and 
MDA-MB-231 cells or E-cadherin shRNA-transfected MCF10A were infected with adeno-scramble shRNA virus or adeno-ANT2 shRNA virus. After 24 h of 
treatment with adeno-virus, cells were stained with Hoechst33342 and analyzed by flow cytometry for measurement of ABCG2 activity.
ABCG2 was highly expressed in stem-like cells of a 
breast cancer cell line, and the expression and 
activity of ABCG2 was down-regulated by 
adeno-ANT2 shRNA virus
Several reports have suggested that CSCs have 
resistance to chemotherapy by expressing P-glyco-
protein and ABCG2. CSCs therefore also have an 
ability to export Hoechst33342, which is a substrate 
for ABCG2. RT-PCR showed that ABCG2 was 
much more highly expressed in the sorted (CD44+/ 
CD24-) cancer stem-like cell population than the 
non-sorted mixed cell population (Figure 5A), which 
may be one of the causes leading to resistance to 
doxorubicin in cancer stem-like cells of MDA-MB-231 
and MCF7 (Figure 4). Therefore, we tested if adeno- 
ANT2 shRNA virus had an effect on the regulation of 
ABCG2 expression. As shown in Figure 5B, ANT2 
shRNA transfection reduced ABCG2 expression of 
progenitor cells. Moreover, ABCB1 expression was 
also down-regulated (Supplementary Data 3). In the 
activity assay of ABCG2 measuring Hoechst33342 
export (Figure 6), ANT2 shRNA treatment resulted 
in the intracellular accumulation of Hoechst33342 in 
cancer stem-like cells, indicating inhibition of ABCG2 
activity by ANT2 shRNA. ABCG2 expression was 
not detected in MCF10A cells, but induced in 
MCF10A
EMT (or MCF10A
E-cad shRNA) cells (Figure 5A). 
ANT2 shRNA also suppressed ABCG2 and its 
activity in MCF10A
EMT cells (Figures 5B and 6). 
Altogether, these results indicated that ANT2 shRNA 
might suppress the expression and activity of 
ABCG2 in breast cancer stem-like cells, thereby 
restoring sensitivity to doxorubicin. 
Discussion 
CSCs exhibit a generalized resistance to apoptosis, 
suggesting that they may not be possible in practice 
in the search for therapies that specifically target 
CSCs. Because CSCs are able to self-renew and 
regenerate tumors, similar to a primary tumor, they 256    Exp. Mol. Med. Vol. 44(4), 251-259, 2012
have been thought to be associated with recurrence 
(Al-Hajj and Clarke, 2004; Ponti et al., 2005; 
Vermeulen et al., 2008). Therefore, it is important to 
study the characteristics of CSCs and to develop 
new therapies targeting them (Chiodi et al., 2011).
    ANT2 has been viewed as an attractive cancer 
therapeutic target in breast cancer (Jang et al., 
2008). We previously reported that plasmid vector- 
based ANT2 RNA interference could be an efficient 
molecular therapeutic method for breast cancer 
which frequently shows high expression of ANT2. 
Moreover, knock-down of ANT2 by shRNA down- 
regulated HER2/neu through suppression of HSP90 
function and inhibited the PI3K/Akt signaling 
pathway, ultimately resulting in suppressed migration 
and invasion of breast cancer cells (Jang et al., 
2010).
    In the present study, we used SP (CD44
highCD24-) 
cells derived from breast cancer cell lines as a rep-
resentative cancer stem-like progenitor cells, ob-
served ANT2 expression markedly up-regulated in 
both cancer stem-like cells and non-cancer 
stem-like cells of breast cancer cell lines, and that 
knock-down of ANT2 by RNA interference efficiently 
induced cell death of cancer stem-like cells as well 
as non- cancer stem-like cells. As another model of 
cancer stem-like cells, we induced epithelial and 
mesenchymal transition in MCF10A cells. MCF10A
EMT 
cells exhibited high expression of ANT2 unlike 
MCF10A cells, and shared some stem-cell like char-
acteristics with SP cells in terms of chemoresistance 
and ABCG2 overexpression. These MCF10A
EMT 
cells were also susceptible to ANT2 shRNA and cell 
death occurred.
        In addition to inducing apoptotic cell death in 
cancer stem-like cells, adeno-ANT2 shRNA virus 
suppressed tumor sphere formation of cancer 
stem-like cells of breast cancer cell lines. Moreover, 
cancer stem-like cells of a breast cancer cell line 
exhibited increased drug (doxorubicin) resistance 
and concomitantly multi-drug resistant-related 
receptors, such as ABCG2, are highly expressed. 
ANT2 shRNA caused progenitor cells and 
MCF10A
EMT cells to overcome chemoresistance 
through the down-regulation of expression and 
activity of ABCG2. 
    RNA interference is a phenomenon that can be 
used to block specific gene expression, and has had 
advantages over other strategies because of its high 
selectivity and potency. Moreover, transfection with 
synthetic dsRNA has been a highly useful method 
for the functional analysis of specific genes in vitro. 
However, dsRNA has been unsuitable for RNAi 
applications for genetic blockade in humans because 
of its low transfection rate and short duration of 
interference. DNA vector-based siRNA technology 
has had some advantages over ds-siRNA, as it 
induces more efficient and stable RNA interference. 
However, DNA plasmid vector-induced siRNA still 
has limitations with respect to the clinical application 
of siRNA technology due to its low transfection 
efficiency. 
    Adenoviruses have been widely used for cancer 
gene therapy because of their high gene transfer 
efficiency and levels of expression. Therefore, in the 
present study, we used an adenovirus expressing 
shRNA to ANT2. Adenoviruses have been used to 
induce RNA interference and here, we report for the 
first time that an adenovirus with an H1-RNA 
promoter effectively blocked p53 by expressing 
siRNA to p53. Further, transduction with several 
adenoviruses expressing siRNAs to certain target 
genes led to the efficient and specific reduction of 
specific mRNAs and encoding proteins (Shen et al., 
2003). Moreover, conditionally replicating adenovirus 
(CRAD) expressed short hairpin RNA was also 
shown to reduce target gene expression
        In conclusion, we believe that adenoviruses 
expressing shRNA to ANT2 can be utilized in anti- 
cancer therapy of breast cancer-stem like cells, and 
will have future use as a chemotherapy-sensitizing 
agent targeting breast cancer-stem like cells. We will 
extend the current investigation of adenovirus-shRNA 
to ANT2 using different cancer models.
Methods 
Cell culture
The human breast carcinoma cell lines, MCF7 and 
MDA-MB-231, were used throughout this study. These 
cells were provided by the Korean Cell Line Bank (Seoul, 
Korea) and were cultured in DMEM supplemented with 
10% FBS, 100 u/ml of penicillin, and 100 μg/ml of 
streptomycin. MCF-10A, a line of healthy epithelial cells 
from human mammary gland (CRL-10317), which provided 
by the American Type Culture Collection (Manassas, VA) 
was used as a control. This cell line was maintained in 
DMEM/Ham Nutrient Mixture F-12 (1:1) with the addition of 
epidermal growth factor (20 ng/ml), cholera enterotoxin 
(100 ng/ml), insulin (10 μg/ml), and hydrocortisone (500 
ng/ml) in the presence of 5% horse serum.
Sorting of cancer stem-like cells (sub-population; 
SP) 
To allow for the isolation of CD44+/CD24- cell populations, 
human breast cancer cell lines (MCF7 and MDA-MB-231) 
were sorted by magnetic cell sorting (MACS; Miltenyi 
Biotech, Auburn, CA) for CD44+ cells prior to SP sorting. In 
MACS, cells were resuspended in 0.1% bovine serum al-
bumin (BSA)-PBS and labeled with phycoerythrin (PE)- 
conjugated CD44 antibody (BD-PharMingen, San Diego, 
California). After addition of the primary antibody, the cells Therapy of breast cancer stem-like cells    257
were incubated with anti-PE microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany). The cell suspension was 
filtered then sorted using the "DOUBLE POSITIVE SORT" 
program of an AutoMACS system (Miltenyi Biotech). Both 
the positive and negative fractions were analyzed by FACS 
to assess sorting efficiency using a FACSCalibur flow cy-
tometer (Becton Dickenson, Mountain View, CA). The se-
lected human breast cancer cell lines were then sorted for 
SP.
Generation of adenoviruses expressing shRNA to 
ANT2
ANT2 shRNA (dsDNA with sense-loop-antisense) were 
cloned into pSilencer H1. The target of ANT2 shRNA was 
complementary to exon 2 accession number NM001152, 
and the sequence was 5'-GCAGAUCACUGCAGAUAAGTT-3'. 
The adenoviruses were constructed using the BD Adeno- 
XTM expression system (BD Biosciences Clontech, Palo 
Alto, CA). Cloned pRNAT was digested with I-CeuI and 
Pl-SceI, and ligated with pre-digested BD adeno-X viral 
DNA (32.6 kb). Following SwaI digestion, adenoviral DNA 
was prepared on a large scale in Escherichia coli, and the 
adenoviral DNA was then transfected into low-passage 
HEK293 cells after PacI digestion. Adenovirus generation 
was confirmed by the appearance of a cytopathic effect. 
The adenoviruses were propagated in HEK293 cells and 
purified using a BD Adeno-XTM purification kit (BD 
Biosciences Clontech). Viral titers were determined using a 
BD Adeno XTM rapid titer kit (BD Biosciences Clontech). 
Transfection 
For transfection, cells were plated on 6-well plates (2 ×10
5 
cells per well) or 100-mm dishes (2 ×10
6 cells), and were 
allowed to adhere for 24 h. Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) was used for the transfections. pSilencer
TM 
3.1-H1 puro ANT2 siRNA vectors or pSilencer
TM3.1-H1 
puro scramble siRNA vectors were transfected into the 
cells. Transfected cells were then cultured for 4 h and the 
culture media were then replaced with fresh media supple-
mented with 10% FBS. The cells were harvested 24-48 h 
after transfection. MCF10A cells expressing either control 
shRNA (control shRNA) or shRNA targeting E-cadherin 
(E-cad shRNA) were generated with Lipofectamine 2000 
(vide supra). Knock-down effect of shRNA was confirmed 
in all experiments (data not shown).
RT-PCR 
Total RNA was extracted using Trizol (Invitrogen) accord-
ing to the manufacturer's instructions. For RT-PCR analy-
sis, 5 μg of total RNA was reverse-transcribed using 
RT-PCR kits (Promega, Madison, WI). PCR was used to 
amplify target cDNA under the following conditions: 35 cy-
cles of 94
oC for 1 min; 55
oC for 1 min; and 72
oC for 2 min. 
The PCR products were analyzed using standard agarose 
gel electrophoresis. The primers used for RT-PCR were as 
follows: ANT2 forward, 5'-CCGCAGCGCCGGAGTCAAA-3' 
and reverse, 5'-AGTCTGTCAAGAATGCTCAA-3'; E-cad-
herin forward, 5'-GACGCGGACGATGAT GTGAAC-3' and 
reverse, 5'-TTGTACGTGGTGGGATTGAAGA-3'; ABCG2 
forward, 5'-CCATAGCCACAGGCCAAAGT-3' and reverse, 
5'-GGGCCACATGATTCTTCCAC-3'; and β-actin forward, 
5'-GGAAATCGTGCGTGACATTAAGG-3' and reverse, 
5'-GGCTTTTAGGATGGCAAG GGA C-3'.
Real-time PCR
Real-time PCR was performed using an IQ5 thermal cycler 
(Bio-Rad, Hercules, CA) in the presence of SYBR-green. 
The optimization of the real-time PCR reaction was per-
formed according to the manufacturer's instructions (User 
Bulletin 2 applied to the SYBR-Green I core reagent proto-
col), but scaled down to 25 μl per reaction. The PCR con-
ditions were standard (SYBR-Green I core reagent proto-
col) and all reagents were provided in the SYBR-Green I 
core reagent kit, including AmpliTaq-polymerase (PE 
Applied-Biosystems). After optimization (see Results sec-
tion), nucleotide primers were used at various concen-
trations for the detection and quantification of signal β-actin 
and coding ANT2. 
Mammosphere formation
To generate mammospheres, single-cell suspensions 
were plated in 100 Φ  dish ultra-low attachment plates 
(30,000 cells/well; Corning, NY) in serum-free MEM sup-
plemented with 20 ng/ml bFGF, 20 ng/ml EGF, and B27 (all 
from Invitrogen). Mammospheres were cultured for 8 days, 
and those collected from non-adherent cultures were quan-
tified with a Multisizer 3 Coulter Counter (sizing range, 
14-336 μm).
Cell viability assay
The viabilities of treated cells were measured using a Cell 
Counting Kit (CCK-8; Dojindo Molecular Technologies, 
Kumamoto, Japan). All assays were performed in triplicate, 
and the results were presented as the mean values of 
three replicate experiments.
Western-blot
For western blot analyses, cells were harvested and were 
lysed with lysis buffer (5 mM/L ethylenediamine tetraacetic 
acid, 300 mM/L NaCl, 0.1% NP-40, 0.5 mM/L NaF, 0.5 
mM/L Na3VO4, 0.5 mM/L phenylmethylsulfonyl fluoride, 
and 10 μg/ml each of aprotinin, pepstatin, and leupeptin; 
Sigma, St Louis, MO). After centrifugation at 15,000 ×g 
for 30 min, the concentrations of supernatant proteins were 
analyzed by a Bradford reagent (Bio-Rad). For analysis of 
protein content, 50 μg of total proteins was electro-
phoresed in 10% SDS-PAGE gel, transferred to poly-
vinylidene difluoride membranes (Millipore, Bedford, MA), 
and were then incubated with the respective antibodies, as 
indicated above. Immunoblots were visualized using an en-
hanced chemiluminescence detection system (Amersham 
Pharmacia Biotech, Uppsala, Sweden). Anti-ANT2, anti- 
ABCG2, and anti-α-tubulin antibodies were obtained from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 258    Exp. Mol. Med. Vol. 44(4), 251-259, 2012
Apoptosis assay
Apoptotic cell death was assessed by flow cytometry assay 
using propidium iodide (PI) staining and Annexin-V fluo-
rescein isothiocyanate (FITC) and PI double-staining. The 
flow cytometry assay using PI staining was performed as 
described in the section on cell cycle analysis. Annexin-V 
and PI double-staining was performed using an Annexin-V 
FITC Apoptosis Detection Kit (R&D Systems, Abingdon, 
UK), following the manufacturer’s protocol. Each group 
was stained and analyzed by a flow cytometer.
FACS (surface staining)
Surface staining was performed with anti-ABCG2 and 
FITC-conjugated anti-mouse IgG antibodies, then analyzed 
by flow cytometry (Epics XL; Coulter, CA). 
FACS (Hoechst 33342 staining)
Hoechst 33342 (Molecular Probes, Eugene, OR) was add-
ed to a concentration of 2-5 μg/ml. Cells were incubated at 
37
oC for 90 min, then placed on ice until analysis. 
Fluorescence from the Hoechst-stained cells was excited 
by 100-150 mW UV from an Innova 305c argon ion laser 
(Coherent, Santa Clara, CA). Fluorescence was monitored 
at 2 emission bands from 400-480 nm (blue) and 690-800 
nm (red).
Statistical analysis
Data were analyzed using the Student's t test, and differ-
ences are considered statistically significant at P ＜0.05.
Supplemental data
Supplemental data include three figures, and can be found 
with this article online at http://e-emm.or.kr/article/article_ 
files/SP-44-4-01.pdf.
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